- Home
- MQY vs CRMD Comparison
MQY vs CRMD Comparison
Compare MQY & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQY
- CRMD
- Stock Information
- Founded
- MQY 1994
- CRMD 2006
- Country
- MQY United States
- CRMD United States
- Employees
- MQY N/A
- CRMD N/A
- Industry
- MQY Investment Bankers/Brokers/Service
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- MQY Finance
- CRMD Health Care
- Exchange
- MQY Nasdaq
- CRMD Nasdaq
- Market Cap
- MQY 776.5M
- CRMD 877.5M
- IPO Year
- MQY N/A
- CRMD 2010
- Fundamental
- Price
- MQY $11.06
- CRMD $11.64
- Analyst Decision
- MQY
- CRMD Strong Buy
- Analyst Count
- MQY 0
- CRMD 7
- Target Price
- MQY N/A
- CRMD $17.33
- AVG Volume (30 Days)
- MQY 184.8K
- CRMD 1.8M
- Earning Date
- MQY 01-01-0001
- CRMD 08-13-2025
- Dividend Yield
- MQY 4.73%
- CRMD N/A
- EPS Growth
- MQY N/A
- CRMD N/A
- EPS
- MQY N/A
- CRMD 0.28
- Revenue
- MQY N/A
- CRMD $82,553,827.00
- Revenue This Year
- MQY N/A
- CRMD $278.96
- Revenue Next Year
- MQY N/A
- CRMD $45.85
- P/E Ratio
- MQY N/A
- CRMD $41.93
- Revenue Growth
- MQY N/A
- CRMD N/A
- 52 Week Low
- MQY $9.82
- CRMD $3.61
- 52 Week High
- MQY $12.52
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- MQY 59.00
- CRMD 47.40
- Support Level
- MQY $10.80
- CRMD $11.40
- Resistance Level
- MQY $10.90
- CRMD $12.02
- Average True Range (ATR)
- MQY 0.09
- CRMD 0.47
- MACD
- MQY 0.01
- CRMD 0.10
- Stochastic Oscillator
- MQY 100.00
- CRMD 68.61
About MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.